ParkinsonCanadaV1, PascalFrancis, Corpus, bibRecord, 000E67

[11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease : Implications for the symptomatic threshold

Identifieur interne : 000E67 ( PascalFrancis/Corpus ); précédent : 000E66; suivant : 000E68

[11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease : Implications for the symptomatic threshold

Auteurs : M. Guttman ; J. Burkholder ; S. J. Kish ; D. Hussey ; A. Wilson ; J. Dasilva ; S. Houle

Source :

Neurology [ 0028-3878 ] ; 1997.

RBID : Pascal:97-0355687

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Tomoscintigraphie, Positon, Dopamine, Protéine transport, Précoce, Exploration, Homme.

English descriptors

KwdEn :
- Carrier protein, Dopamine, Early, Emission tomography, Exploration, Human, Parkinson disease, Positron.

Abstract

Article abstract-To estimate the threshold of nigrostriatal dysfunction required for symptomatic Parkinson's disease (PD), we employed [¹¹C ]RTI-32 and PET to study the dopamine transporter in striatal subdivisions of 11 L-dopa-naive patients with very early parkinsonism. As compared with the controls (N = 10), the PD group had on the side contralateral to the maximal clinical symptoms, significantly reduced binding in the posterior putamen (-56%) and anterior putamen (-28%), with the reduction in caudate (- 12%) not significantly different. To the extent that dopamine transporter binding accurately reflects the number of nigrostriatal dopamine nerve terminals, these findings suggest that the clinical threshold for PD in the middle-age human is approximately 50% loss of dopaminergic innervation to the posterior putamen. Our data also suggest that damage to the putamen component of the striatum is sufficient for the clinical expression of PD.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0028-3878`
A02	`01`			`@0 NEURAI`
A03		`1`		`@0 Neurology`
A05				`@2 48`
A06				`@2 6`
A08	`01`	`1`	`ENG`	`@1 [¹¹C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease : Implications for the symptomatic threshold`
A11	`01`	`1`		`@1 GUTTMAN (M.)`
A11	`02`	`1`		`@1 BURKHOLDER (J.)`
A11	`03`	`1`		`@1 KISH (S. J.)`
A11	`04`	`1`		`@1 HUSSEY (D.)`
A11	`05`	`1`		`@1 WILSON (A.)`
A11	`06`	`1`		`@1 DASILVA (J.)`
A11	`07`	`1`		`@1 HOULE (S.)`
A14	`01`			`@1 Human Neurochemical Pathology Laboratory @3 CAN @Z 1 aut. @Z 3 aut.`
A14	`02`			`@1 Clarke Institute of Psychiatry, Division of Neurology, University of Toronto Faculty of Medicine @2 Toronto, Ontario @3 CAN @Z 1 aut.`
A14	`03`			`@1 PET Center @3 USA @Z 2 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut. @Z 7 aut.`
A20				`@1 1578-1583`
A21				`@1 1997`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 6345 @5 354000061850460190`
A44				`@0 0000 @1 © 1997 INIST-CNRS. All rights reserved.`
A45				`@0 21 ref.`
A47	`01`	`1`		`@0 97-0355687`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Neurology`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Article abstract-To estimate the threshold of nigrostriatal dysfunction required for symptomatic Parkinson's disease (PD), we employed [¹¹C ]RTI-32 and PET to study the dopamine transporter in striatal subdivisions of 11 L-dopa-naive patients with very early parkinsonism. As compared with the controls (N = 10), the PD group had on the side contralateral to the maximal clinical symptoms, significantly reduced binding in the posterior putamen (-56%) and anterior putamen (-28%), with the reduction in caudate (- 12%) not significantly different. To the extent that dopamine transporter binding accurately reflects the number of nigrostriatal dopamine nerve terminals, these findings suggest that the clinical threshold for PD in the middle-age human is approximately 50% loss of dopaminergic innervation to the posterior putamen. Our data also suggest that damage to the putamen component of the striatum is sufficient for the clinical expression of PD.
C02	`01`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Tomoscintigraphie @5 04`
C03	`02`	`X`	`ENG`	`@0 Emission tomography @5 04`
C03	`02`	`X`	`SPA`	`@0 Tomocentelleografía @5 04`
C03	`03`	`X`	`FRE`	`@0 Positon @5 05`
C03	`03`	`X`	`ENG`	`@0 Positron @5 05`
C03	`03`	`X`	`GER`	`@0 Positron @5 05`
C03	`03`	`X`	`SPA`	`@0 Positrón @5 05`
C03	`04`	`X`	`FRE`	`@0 Dopamine @2 NK @2 FR @5 07`
C03	`04`	`X`	`ENG`	`@0 Dopamine @2 NK @2 FR @5 07`
C03	`04`	`X`	`SPA`	`@0 Dopamina @2 NK @2 FR @5 07`
C03	`05`	`X`	`FRE`	`@0 Protéine transport @5 10`
C03	`05`	`X`	`ENG`	`@0 Carrier protein @5 10`
C03	`05`	`X`	`SPA`	`@0 Proteína transportador @5 10`
C03	`06`	`X`	`FRE`	`@0 Précoce @5 16`
C03	`06`	`X`	`ENG`	`@0 Early @5 16`
C03	`06`	`X`	`SPA`	`@0 Precoz @5 16`
C03	`07`	`X`	`FRE`	`@0 Exploration @5 17`
C03	`07`	`X`	`ENG`	`@0 Exploration @5 17`
C03	`07`	`X`	`SPA`	`@0 Exploración @5 17`
C03	`08`	`X`	`FRE`	`@0 Homme @5 20`
C03	`08`	`X`	`ENG`	`@0 Human @5 20`
C03	`08`	`X`	`SPA`	`@0 Hombre @5 20`
C07	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
C07	`06`	`X`	`FRE`	`@0 Exploration radioisotopique @5 45`
C07	`06`	`X`	`ENG`	`@0 Radionuclide study @5 45`
C07	`06`	`X`	`SPA`	`@0 Exploración radioisotópica @5 45`
N21				`@1 209`

Format Inist (serveur)

NO :	PASCAL 97-0355687 INIST
ET :	[¹¹C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease : Implications for the symptomatic threshold
AU :	GUTTMAN (M.); BURKHOLDER (J.); KISH (S. J.); HUSSEY (D.); WILSON (A.); DASILVA (J.); HOULE (S.)
AF :	Human Neurochemical Pathology Laboratory/Canada (1 aut., 3 aut.); Clarke Institute of Psychiatry, Division of Neurology, University of Toronto Faculty of Medicine/Toronto, Ontario/Canada (1 aut.); PET Center/Etats-Unis (2 aut., 4 aut., 5 aut., 6 aut., 7 aut.)
DT :	Publication en série; Niveau analytique
SO :	Neurology; ISSN 0028-3878; Coden NEURAI; Etats-Unis; Da. 1997; Vol. 48; No. 6; Pp. 1578-1583; Bibl. 21 ref.
LA :	Anglais
EA :	Article abstract-To estimate the threshold of nigrostriatal dysfunction required for symptomatic Parkinson's disease (PD), we employed [¹¹C ]RTI-32 and PET to study the dopamine transporter in striatal subdivisions of 11 L-dopa-naive patients with very early parkinsonism. As compared with the controls (N = 10), the PD group had on the side contralateral to the maximal clinical symptoms, significantly reduced binding in the posterior putamen (-56%) and anterior putamen (-28%), with the reduction in caudate (- 12%) not significantly different. To the extent that dopamine transporter binding accurately reflects the number of nigrostriatal dopamine nerve terminals, these findings suggest that the clinical threshold for PD in the middle-age human is approximately 50% loss of dopaminergic innervation to the posterior putamen. Our data also suggest that damage to the putamen component of the striatum is sufficient for the clinical expression of PD.
CC :	002B17G
FD :	Parkinson maladie; Tomoscintigraphie; Positon; Dopamine; Protéine transport; Précoce; Exploration; Homme
FG :	Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Exploration radioisotopique
ED :	Parkinson disease; Emission tomography; Positron; Dopamine; Carrier protein; Early; Exploration; Human
EG :	Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Radionuclide study
GD :	Positron
SD :	Parkinson enfermedad; Tomocentelleografía; Positrón; Dopamina; Proteína transportador; Precoz; Exploración; Hombre
LO :	INIST-6345.354000061850460190
ID :	97-0355687

Links to Exploration step

Pascal:97-0355687

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">[<sup>11</sup>
C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease : Implications for the symptomatic threshold</title>
<author><name sortKey="Guttman, M" sort="Guttman, M" uniqKey="Guttman M" first="M." last="Guttman">M. Guttman</name>
<affiliation><inist:fA14 i1="01"><s1>Human Neurochemical Pathology Laboratory</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Clarke Institute of Psychiatry, Division of Neurology, University of Toronto Faculty of Medicine</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Burkholder, J" sort="Burkholder, J" uniqKey="Burkholder J" first="J." last="Burkholder">J. Burkholder</name>
<affiliation><inist:fA14 i1="03"><s1>PET Center</s1>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kish, S J" sort="Kish, S J" uniqKey="Kish S" first="S. J." last="Kish">S. J. Kish</name>
<affiliation><inist:fA14 i1="01"><s1>Human Neurochemical Pathology Laboratory</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hussey, D" sort="Hussey, D" uniqKey="Hussey D" first="D." last="Hussey">D. Hussey</name>
<affiliation><inist:fA14 i1="03"><s1>PET Center</s1>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wilson, A" sort="Wilson, A" uniqKey="Wilson A" first="A." last="Wilson">A. Wilson</name>
<affiliation><inist:fA14 i1="03"><s1>PET Center</s1>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dasilva, J" sort="Dasilva, J" uniqKey="Dasilva J" first="J." last="Dasilva">J. Dasilva</name>
<affiliation><inist:fA14 i1="03"><s1>PET Center</s1>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Houle, S" sort="Houle, S" uniqKey="Houle S" first="S." last="Houle">S. Houle</name>
<affiliation><inist:fA14 i1="03"><s1>PET Center</s1>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">97-0355687</idno>
<date when="1997">1997</date>
<idno type="stanalyst">PASCAL 97-0355687 INIST</idno>
<idno type="RBID">Pascal:97-0355687</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000E67</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">[<sup>11</sup>
C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease : Implications for the symptomatic threshold</title>
<author><name sortKey="Guttman, M" sort="Guttman, M" uniqKey="Guttman M" first="M." last="Guttman">M. Guttman</name>
<affiliation><inist:fA14 i1="01"><s1>Human Neurochemical Pathology Laboratory</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Clarke Institute of Psychiatry, Division of Neurology, University of Toronto Faculty of Medicine</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Burkholder, J" sort="Burkholder, J" uniqKey="Burkholder J" first="J." last="Burkholder">J. Burkholder</name>
<affiliation><inist:fA14 i1="03"><s1>PET Center</s1>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kish, S J" sort="Kish, S J" uniqKey="Kish S" first="S. J." last="Kish">S. J. Kish</name>
<affiliation><inist:fA14 i1="01"><s1>Human Neurochemical Pathology Laboratory</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hussey, D" sort="Hussey, D" uniqKey="Hussey D" first="D." last="Hussey">D. Hussey</name>
<affiliation><inist:fA14 i1="03"><s1>PET Center</s1>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wilson, A" sort="Wilson, A" uniqKey="Wilson A" first="A." last="Wilson">A. Wilson</name>
<affiliation><inist:fA14 i1="03"><s1>PET Center</s1>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dasilva, J" sort="Dasilva, J" uniqKey="Dasilva J" first="J." last="Dasilva">J. Dasilva</name>
<affiliation><inist:fA14 i1="03"><s1>PET Center</s1>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Houle, S" sort="Houle, S" uniqKey="Houle S" first="S." last="Houle">S. Houle</name>
<affiliation><inist:fA14 i1="03"><s1>PET Center</s1>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Neurology</title>
<title level="j" type="abbreviated">Neurology</title>
<idno type="ISSN">0028-3878</idno>
<imprint><date when="1997">1997</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Neurology</title>
<title level="j" type="abbreviated">Neurology</title>
<idno type="ISSN">0028-3878</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Carrier protein</term>
<term>Dopamine</term>
<term>Early</term>
<term>Emission tomography</term>
<term>Exploration</term>
<term>Human</term>
<term>Parkinson disease</term>
<term>Positron</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Tomoscintigraphie</term>
<term>Positon</term>
<term>Dopamine</term>
<term>Protéine transport</term>
<term>Précoce</term>
<term>Exploration</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Article abstract-To estimate the threshold of nigrostriatal dysfunction required for symptomatic Parkinson's disease (PD), we employed [<sup>11</sup>
C ]RTI-32 and PET to study the dopamine transporter in striatal subdivisions of 11 L-dopa-naive patients with very early parkinsonism. As compared with the controls (N = 10), the PD group had on the side contralateral to the maximal clinical symptoms, significantly reduced binding in the posterior putamen (-56%) and anterior putamen (-28%), with the reduction in caudate (- 12%) not significantly different. To the extent that dopamine transporter binding accurately reflects the number of nigrostriatal dopamine nerve terminals, these findings suggest that the clinical threshold for PD in the middle-age human is approximately 50% loss of dopaminergic innervation to the posterior putamen. Our data also suggest that damage to the putamen component of the striatum is sufficient for the clinical expression of PD.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0028-3878</s0>
</fA01>
<fA02 i1="01"><s0>NEURAI</s0>
</fA02>
<fA03 i2="1"><s0>Neurology</s0>
</fA03>
<fA05><s2>48</s2>
</fA05>
<fA06><s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>[<sup>11</sup>
C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease : Implications for the symptomatic threshold</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>GUTTMAN (M.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BURKHOLDER (J.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>KISH (S. J.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>HUSSEY (D.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>WILSON (A.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>DASILVA (J.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>HOULE (S.)</s1>
</fA11>
<fA14 i1="01"><s1>Human Neurochemical Pathology Laboratory</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Clarke Institute of Psychiatry, Division of Neurology, University of Toronto Faculty of Medicine</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>PET Center</s1>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA20><s1>1578-1583</s1>
</fA20>
<fA21><s1>1997</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>6345</s2>
<s5>354000061850460190</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 1997 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>21 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>97-0355687</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Neurology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Article abstract-To estimate the threshold of nigrostriatal dysfunction required for symptomatic Parkinson's disease (PD), we employed [<sup>11</sup>
C ]RTI-32 and PET to study the dopamine transporter in striatal subdivisions of 11 L-dopa-naive patients with very early parkinsonism. As compared with the controls (N = 10), the PD group had on the side contralateral to the maximal clinical symptoms, significantly reduced binding in the posterior putamen (-56%) and anterior putamen (-28%), with the reduction in caudate (- 12%) not significantly different. To the extent that dopamine transporter binding accurately reflects the number of nigrostriatal dopamine nerve terminals, these findings suggest that the clinical threshold for PD in the middle-age human is approximately 50% loss of dopaminergic innervation to the posterior putamen. Our data also suggest that damage to the putamen component of the striatum is sufficient for the clinical expression of PD.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Tomoscintigraphie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Emission tomography</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Tomocentelleografía</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Positon</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Positron</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="GER"><s0>Positron</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Positrón</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Dopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Protéine transport</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Carrier protein</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Proteína transportador</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Précoce</s0>
<s5>16</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Early</s0>
<s5>16</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Precoz</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Exploration</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Exploration</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Exploración</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Exploration radioisotopique</s0>
<s5>45</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Radionuclide study</s0>
<s5>45</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Exploración radioisotópica</s0>
<s5>45</s5>
</fC07>
<fN21><s1>209</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 97-0355687 INIST</NO>
<ET>[<sup>11</sup>
C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease : Implications for the symptomatic threshold</ET>
<AU>GUTTMAN (M.); BURKHOLDER (J.); KISH (S. J.); HUSSEY (D.); WILSON (A.); DASILVA (J.); HOULE (S.)</AU>
<AF>Human Neurochemical Pathology Laboratory/Canada (1 aut., 3 aut.); Clarke Institute of Psychiatry, Division of Neurology, University of Toronto Faculty of Medicine/Toronto, Ontario/Canada (1 aut.); PET Center/Etats-Unis (2 aut., 4 aut., 5 aut., 6 aut., 7 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Neurology; ISSN 0028-3878; Coden NEURAI; Etats-Unis; Da. 1997; Vol. 48; No. 6; Pp. 1578-1583; Bibl. 21 ref.</SO>
<LA>Anglais</LA>
<EA>Article abstract-To estimate the threshold of nigrostriatal dysfunction required for symptomatic Parkinson's disease (PD), we employed [<sup>11</sup>
C ]RTI-32 and PET to study the dopamine transporter in striatal subdivisions of 11 L-dopa-naive patients with very early parkinsonism. As compared with the controls (N = 10), the PD group had on the side contralateral to the maximal clinical symptoms, significantly reduced binding in the posterior putamen (-56%) and anterior putamen (-28%), with the reduction in caudate (- 12%) not significantly different. To the extent that dopamine transporter binding accurately reflects the number of nigrostriatal dopamine nerve terminals, these findings suggest that the clinical threshold for PD in the middle-age human is approximately 50% loss of dopaminergic innervation to the posterior putamen. Our data also suggest that damage to the putamen component of the striatum is sufficient for the clinical expression of PD.</EA>
<CC>002B17G</CC>
<FD>Parkinson maladie; Tomoscintigraphie; Positon; Dopamine; Protéine transport; Précoce; Exploration; Homme</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Exploration radioisotopique</FG>
<ED>Parkinson disease; Emission tomography; Positron; Dopamine; Carrier protein; Early; Exploration; Human</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Radionuclide study</EG>
<GD>Positron</GD>
<SD>Parkinson enfermedad; Tomocentelleografía; Positrón; Dopamina; Proteína transportador; Precoz; Exploración; Hombre</SD>
<LO>INIST-6345.354000061850460190</LO>
<ID>97-0355687</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E67 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000E67 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:97-0355687
   |texte=   [11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease : Implications for the symptomatic threshold
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

[11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease : Implications for the symptomatic threshold

[11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease : Implications for the symptomatic threshold

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri